---
trial_id: 254
discovery_date: 2022-03-29 21:28:27.965984
date: 2022-03-29 21:28:27.965984
title: "A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe..."
summary: |
  <p>EudraCT Number: 2020-002700-39<br />Sponsor Protocol Number: CBAF312D2301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-09-10<br />Medical condition: Multiple Sclerosis in pediatric patients<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/EE">EE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/SK">SK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/HR">HR</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002700-39'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2020-002700-39<br />Sponsor Protocol Number: CBAF312D2301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-09-10<br />Medical condition: Multiple Sclerosis in pediatric patients<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/EE">EE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/SK">SK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/HR">HR</a> (Ongoing)</p>